Chronic Weight Management therapy (DBCOND0106162)

Identifiers

Synonyms

Chronic Weight Management

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Liraglutide	A GLP-1 analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.	Glucagon-like peptide 1 receptortarget Dipeptidyl peptidase 4enzyme Neprilysinenzyme Albumincarrier
Naltrexone	A narcotic antagonist used in opioid overdose.	Mu-type opioid receptortarget Kappa-type opioid receptortarget Delta-type opioid receptortarget UDP-glucuronosyltransferase 1A1enzyme Sigma non-opioid intracellular receptor 1target
Phentermine	A sympathomimetic anorectic agent used as a short-term adjunct therapy that is included in a regimen of weight reduction in cases of exogenous obesity.	Sodium-dependent noradrenaline transportertarget Sodium-dependent dopamine transportertarget Amine oxidase [flavin-containing] Atarget Amine oxidase [flavin-containing] Btarget Sodium-dependent serotonin transportertarget Pro-neuropeptide Ytarget Cytochrome P450 3A4enzyme
Semaglutide	A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults.	Albumincarrier Dipeptidyl peptidase 4enzyme Neprilysinenzyme Glucagon-like peptide 1 receptortarget Lipoprotein lipaseenzyme
Setmelanotide	A drug indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome.	Melanocortin receptor 4target
Tirzepatide	A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.	Glucagon-like peptide 1 receptortarget Albumincarrier Gastric inhibitory polypeptide receptortarget
Topiramate	An anticonvulsant drug used in the control of epilepsy and in the prophylaxis and treatment of migraines.	Gamma-aminobutyric acid receptor subunit alpha-1target Voltage-gated sodium channel alpha subunittarget Carbonic anhydrase 2target Carbonic anhydrase 4target Kainate receptorstarget Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme Carbonic anhydrase 1target Carbonic anhydrase 3target Voltage gated L-type calcium channeltarget Voltage-dependent R-type calcium channeltarget Albumincarrier ATP-dependent translocase ABCB1transporter 5'-AMP-activated protein kinasetransporter Glutamate receptor ionotropic, kainate 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01987427	A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults	Lorcaserin Phentermine	treatment	4	completed